Alexandria Real Estate Equities, Inc., widely known as ARE, announced on Monday its long-term tenant, AstraZeneca PLC, plans to invest $300 million in a state-of-the-art cell therapy manufacturing facility. This facility is located at the Alexandria Centre for Life Science in Rockville, Maryland and is anticipated to generate more than 150 high-level job opportunities.
ARE revealed that AstraZeneca anticipates the new facility to handle the biomanufacturing of T-cell therapies for both clinical trials and commercial applications.
Ahead of the market opening, Alexandria's stock was seen trading at $116.22, marking a slight increase of 0.02% on the New York Stock Exchange.
